Search Results - "Seymour, M.T"

The prevalence and outcomes of frailty in older cancer patients: a systematic review by Handforth, C., Clegg, A., Young, C., Simpkins, S., Seymour, M.T., Selby, P.J., Young, J.

“…Frailty is a state of vulnerability to poor resolution of homeostasis following a stressor event, such as chemotherapy or cancer surgery. Better knowledge of…”
Get full text

6097 POSTER Ciclosporin in Combination With Irinotecan for Chemoresistant Advanced Colorectal Cancer – Results of PICCOLO, a Large Randomised Trial With Prospective Molecular Stratification by Middleton, G.W, Brown, S.R, Gwyther, S.J, Maughan, T.S, Wadsley, J, Chau, I, Richman, S, Olivier, C, Marshall, H, Seymour, M.T

Get full text

6007 ORAL Panitumumab in Combination With Irinotecan for Chemoresistant Advanced Colorectal Cancer: Results of PICCOLO, a Large Randomised Trial With Prospective Molecular Stratification by Seymour, M.T, Brown, S.R, Richman, S, Middleton, G.W, Maughan, T.S, Maisey, N, Hill, M, Olivier, C, Napp, V, Quirke, P

Get full text

Factors Predicting Outcome for Advanced Gastroesophageal Cancer in Elderly Patients Receiving Palliative Chemotherapy by Lord, S.R, Hall, P.S, McShane, P, Brown, J, Seymour, M.T

“…Abstract Aims Most patients with advanced gastroesophageal cancer are elderly, but current standard regimens have emerged from trials predominantly involving…”
Get full text

O.10 Chemotherapy choices and doses in frail and elderly patients with advanced colorectal cancer: an MRC randomised clinical trial (FOCUS2) by Seymour, M.T, Maughan, T.S, Wasan, H.S, Brewster, A.E, Shepherd, S.F, O'Mahoney, M.S, May, B.R, Thompson, L.C, Meade, Langley, R.E

Get full text

A feasibility, pharmacokinetic and frequency-escalation trial of intraperitoneal chemotherapy in high risk gastrointestinal tract cancer by Seymour, M.T, Trigonis, I, Finan, P.J, Halstead, F, Dunham, R, Wilson, G, Farrugia, D, Chester, J.D, King, J, Brown, C.B, Slevin, M.L, Joel, S.P

“…Abstract Aims To assess the feasibility, pharmacokinetics and maximum tolerable frequency (MTF) of intraperitoneal (IP) 5-fluorouracil and leucovorin (FU/LV)…”
Get full text

6LBA Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN) by Maughan, T, Adams, R.A, Smith, C.G, Seymour, M.T, Wilson, R, Meade, A.M, Fisher, D, Madi, A, Cheadle, J, Kaplan, R

Get full text

6125 Topoisomerase-1 (Topo1) as a predictive and prognostic factor in colorectal cancer chemotherapy by Richman, S.D, Thompson, L.C, Quirke, P, Langley, R.E, Wasan, H.S, Daly, C, Parmar, M.K.B, Kaplan, R, Seymour, M.T

Get full text

15LBA Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN) by Adams, R, Wilson, R, Seymour, M.T, Meade, A.M, Madi, A, Cassidy, J, Fisher, D, Kenny, S, Kaplan, R, Maughan, T.S

Get full text

532PD - Pre-operative FOLFOX chemotherapy in advanced colon cancer: Pathology analysis of the FOxTROT trial by West, N., Murakami, K., Magill, L., Gray, R., Handley, K., Seymour, M.T., Morton, D., Quirke, P.

“…The phase III international FOxTROT trial assessed the effectiveness of pre-operative chemotherapy in locally advanced colon cancer. Patients were randomised…”
Get full text

Pre-operative FOLFOX chemotherapy in advanced colon cancer: Pathology analysis of the FOxTROT trial by West, N., Murakami, K., Magill, L., Gray, R., Handley, K., Seymour, M.T., Morton, D., Quirke, P.

Get full text

337P Prediction of poor response to oxaliplatin by an RNA signature derived and validated in colorectal cancer clinical trials by Hassanieh, S., Domingo, E., Blake, A., Fisher, D., Redmond, K.L., Richman, S.D., Walker, S.M., Quirke, P., Wilson, R.H., Kennedy, R., Tomlinson, I., Kaplan, R.S., L. brown, Dunne, P., Seymour, M.T., Morton, D., Adams, R.A., West, N., Maughan, T.

Get full text

Chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): Quality of Life (QoL) results from the GO2 phase III trial by Hall, P., Swinson, D., Lord, S., Handforth, C., Cairns, D., Marshall, H., Petty, R., Bennett, M., Velikova, G., Seymour, M.T.

Get full text

LBA46 - Chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): Quality of Life (QoL) results from the GO2 phase III trial by Hall, P., Swinson, D., Lord, S., Handforth, C., Cairns, D., Marshall, H., Petty, R., Bennett, M., Velikova, G., Seymour, M.T.

“…Many pts with aGOAC are elderly and/or frail. GO2 [ASCO 2019 #4006] found that lower dose OxaliplatinCapecitabine (OCap) led to non-inferior progression free…”
Get full text

583P - Choosing the right strategy based on individualized treatment effect predictions: Combination versus sequential chemotherapy in patients with metastatic colorectal cancer by Koopman, M., Kwakman, J.J., van Kruijsdijk, R.C.M., Elias, S.G., Seymour, M.T., Meade, A.M., Visseren, F., Punt, C.J.A.

“…Translating results from randomized trials to individual patients is challenging since treatment effects may vary due to heterogeneous prognostic…”
Get full text

Choosing the right strategy based on individualized treatment effect predictions: Combination versus sequential chemotherapy in patients with metastatic colorectal cancer by Koopman, M., Kwakman, J.J., van Kruijsdijk, R.C.M., Elias, S.G., Seymour, M.T., Meade, A.M., Visseren, F., Punt, C.J.A.

Get full text

8LB Chemotherapy choices and doses in frail and elderly patients with advanced colorectal cancer: an MRC randomised clinical trial (FOCUS2) by Seymour, M.T, Maughan, T.S, Wasan, H.S, Brewster, A.E, Shepherd, S.F, O'Mahoney, M.S, May, B.R, Thompson, L.C, Meade, A, Langley, R.E

Get full text

InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease - An International Rare Cancers Initiative (IRCI) trial by Rao, S., Sclafani, F., Eng, C., Grønlie Guren, M., Adams, R.A., Benson, A., Sebag-Montefiore, D., Segelov, E., Bryant, A., Peckitt, C., Roy, A., Seymour, M.T., Welch, J., Saunders, M.P., Muirhead, R., Bridgewater, J., Falk, S., Glynne-Jones, R., Arnold, D., Cunningham, D.

Get full text

Concomitant medications in cancer patients: should we be more active in their management? by Lord, S., Hall, P.S., Seymour, M.T.

Get full text

Are we representing the true population in oncology trials? by Lord, S.R., Hall, P.S., Seymour, M.T.

Get full text